🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bristol
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Bristol

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 44 Bristol 18 Manchester 17 Oxford 15 Birmingham 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca23 Eli Lilly and Company18 Merck Sharp & Dohme LLC17 Boehringer Ingelheim10 Janssen Research & Development, LLC9 Clear sponsor filter
Site city
London44 Bristol18 Manchester17 Oxford15 Birmingham14
All 106 cities
Target enrolment
to
18 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belfast, Birmingham, Blackpool, Bodelwyddan, Bradford on Avon, Bristol, Bromborough, Enfield
2025-09-02
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole
2025-03-28
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
Eli Lilly and Company
Phase 3
320
Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage
2024-03-15
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Blackburn, Bristol, Coventry, Dundee, Ely, Fowey, Hull, Ipswich
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Active, closed
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT04088409Uveitis
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/bristol

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.